Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PCI Biotech Holding ASA ( (DE:4QG) ) has provided an update.
PCI Biotech has announced an update on its operational evaluation, highlighting the critical nature of its liquidity position and the uncertainty surrounding its ability to continue as a going concern. The company is currently focused on a new bioprocessing technology evaluation under a material transfer agreement, with no active strategic discussions or financial terms disclosed. The management structure has been streamlined to consist solely of the CEO, with the board of directors assuming additional roles in the subsidiary.
More about PCI Biotech Holding ASA
PCI Biotech is a biopharmaceutical company focused on developing and commercializing new technologies and novel therapies through its photochemical technology platform, originating from research at the Oslo University Hospital. The platform was previously under development in photochemical lysis for viral vector manufacturing and photochemical internalisation for unlocking various modalities.
Average Trading Volume: 907,445
Current Market Cap: NOK11.94M
For a thorough assessment of 4QG stock, go to TipRanks’ Stock Analysis page.